✨
AI Summary
- Celyad Oncology CMO Dr. Charlie Morris discusses allogeneic versus autologous CAR-T therapies.
- He highlights the benefits and challenges of the allogeneic approach.
- A non-gene edited shRNA approach may offer improved efficacy and safety.
Guests on This Episode
CM
Charlie Morris
1 podcast appearance